智通财经APP获悉，香港联交所最新数据显示，2月3日，FMR LLC减持中石化炼化工程(02386)31.55万 股，每股作价7.44港元，总金额约为234.732万港元。减持后最新持股数目约为9970.14万股，持股比例 为6.99%。 ...

智通财经APP获悉，香港联交所最新资料显示，2月3日，FMR LLC增持中国石油化工股份(00386)2164.6 万股，每股作价5.2836港元，总金额约为1.14亿港元。增持后最新持股数目约为11.95亿股，最新持股比 例为5.02%。 ...

增持后，FMR LLC最新持股数目为5903.538万股，持股比例由6.97%上升至7.02%。 格隆汇2月5日丨根据联交所最新权益披露资料显示，2026年2月2日，康臣药业(01681.HK)获FMR LLC 在场内以每股均价17.4026港元增持34.9万股，涉资约607.35万港元。 | 废墟序财 | 大股票董事/股票行政人員名 作出發器的 廣人/費出或廖及的 舞發的平均價 | | | 持真量益的股份數据 信已發行的 有嚴重性的目開 相應法屬發份 價權證權益 | | --- | --- | --- | --- | --- | | | BLIGH 股份管目 | | | ( 椅金製上述 * 克 南投票哪段(日/月/年) 雕芸 | | CS20260205E00328 FMR LLC | 110:1(L) | 349,000(L) | HKD 17.4026 | COMPE 59,035,375(L) 7,02(L)02/02/2026 | | 股份代替: | 01681 | 廉臣药雕集团有限公司 | 上市法國名稱: | 日期(日/月/年): | | --- | --- | --- | --- | --- | ...

Group 1 - FMR LLC reduced its stake in Kwan Tong Group (00148) by 4.6335 million shares at a price of HKD 31.2782 per share, totaling approximately HKD 145 million [1][3] - After the reduction, FMR LLC's remaining shareholding is approximately 87.3961 million shares, representing a new ownership percentage of 7.89% [1][3]

Core Viewpoint - FMR LLC has reduced its stake in Kwan Tong Group (00148) by selling 4.6335 million shares at a price of HKD 31.2782 per share, totaling approximately HKD 145 million, resulting in a new holding of about 87.3961 million shares, representing 7.89% of the company [1] Summary by Category - **Share Reduction**: FMR LLC sold 4.6335 million shares of Kwan Tong Group [1] - **Transaction Details**: The shares were sold at a price of HKD 31.2782 each, amounting to a total of approximately HKD 145 million [1] - **Post-Transaction Holdings**: After the sale, FMR LLC's remaining shares in Kwan Tong Group are approximately 87.3961 million, with a holding percentage of 7.89% [1]

Group 1 - FMR LLC reduced its stake in Kwan Hung Holdings (00148) by 4.6335 million shares at a price of HKD 31.2782 per share, totaling approximately HKD 145 million [1] - After the reduction, FMR LLC's remaining shareholding is approximately 87.3961 million shares, representing a holding percentage of 7.89% [1]

香港联交所最新资料显示，1月20日，FMR LLC增持泉峰控股(02285)43.66万股，每股作价25.0387港 元，总金额约为1093.19万港元。增持后最新持股数目约为2586.29万股，最新持股比例为5.06%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月20日，FMR LLC增持泉峰控股(02285)43.66万股，每 股作价25.0387港元，总金额约为1093.19万港元。增持后最新持股数目约为2586.29万股，最新持股比例 为5.06%。 ...

格隆汇1月22日｜香港交易所信息显示，FMR LLC在中国人寿H股的持股比例于01月19日从5.04%降至 4.95%，卖出的平均股价为32.0682港元。 ...

Company Overview - Structure Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oral therapeutics for chronic diseases with high unmet need, including Type 2 diabetes, obesity, and pulmonary and cardiovascular diseases [9] - The company has a market capitalization of $5.60 billion and employs 163 people [5] - The net income for the trailing twelve months (TTM) is -$210.69 million, with a one-year price change of 212.55% as of January 12, 2026 [5] Recent Transactions - FMR LLC, a 10% owner of Structure Therapeutics, indirectly sold 52,356 shares for approximately $3.8 million on December 8, 2025 [2][3] - This sale represents the largest single open-market transaction for FMR LLC, significantly exceeding the recent median sell size of 21,997 shares [8] - Following the transaction, FMR LLC holds 471,207 shares indirectly, with a post-transaction value of approximately $33.92 million [3] Market Context - The shares were sold at a price of around $71.98 per share, which was higher than the market closing price of $69.98 on the same day [8] - Shortly after the sale, on December 11, 2025, Structure Therapeutics announced the closing of a public offering that raised approximately $748 million, indicating strong stakeholder support [12] Investment Considerations - Investors should note that FMR LLC purchased American Depositary Shares (ADS), which are fractional shares of ordinary shares offered on the U.S. stock market, allowing American investors to invest in foreign companies [10] - Holding ADS may incur occasional fees, typically ranging from 1 to 5 cents per share [11]